Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuropathologie, Lyon, Cedex, France; Université Claude Bernard Lyon 1, Lyon, France; Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neuro-Oncologie, Lyon, Cedex, France; Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Anatomie et Cytologie Pathologiques, Lyon, Cedex, France; CHU Toulouse, Hôpital de Rangueil, Service d'Anatomie et Cytologie Pathologique, Toulouse, France; CHU Toulouse, Hôpital Pierre-Paul Riquet, Service de Neurologie, Toulouse, France; CHU Saint-Etienne, Hôpital Nord, Service d'Anatomie et Cytologie Pathologique, Saint-Etienne, France; CHU de Tours, Hôpital Bretonneau, Service d'anatomie et cytologie pathologiques, Tours, Cedex, France; CHU de Nice, Hôpital Pasteur, Service d'anatomie et cytologie pathologiques, Nice, France; CHU de Nice, Hôpital Pasteur, Service de neurologie, Nice, France; Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Neurochirurgie D, Lyon, Cedex, France; Institut NeuroMyoGene, INSERM 1217/CNRS 5310, Université de Lyon, Lyon, France.
Neuro Oncol. 2017 Aug 1;19(8):1127-1134. doi: 10.1093/neuonc/now274.
Diffuse H3 K27M-mutant gliomas occur primarily in children but can also be encountered in adults. The aim of this study was to describe the characteristics of H3 K27M-mutant gliomas in adults.
We analyzed the characteristics of 21 adult H3 K27M-mutant gliomas and compared them with those of 135 adult diffuse gliomas without histone H3 and without isocitrate dehydrogenase (IDH) mutation (IDH/H3 wild type).
The median age at diagnosis in H3 K27M-mutant gliomas was 32 years (range: 18-82 y). All tumors had a midline location (spinal cord n = 6, thalamus n = 5, brainstem n = 5, cerebellum n = 3, hypothalamus n = 1, and pineal region n = 1) and were IDH and BRAF-V600E wild type. The identification of an H3 K27M mutation significantly impacted the diagnosis in 3 patients (14%) for whom the histological aspect initially suggested a diffuse low-grade glioma and in 7 patients (33%) for whom pathological analysis hesitated between a diffuse glioma, ganglioglioma, or pilocytic astrocytoma. Compared with IDH/H3 wild-type gliomas, H3 K27M-mutant gliomas were diagnosed at an earlier age (32 vs 64 y, P < .001), always had a midline location (21/21 vs 21/130, P < .001), less frequently had a methylated MGMT promoter (1/21 vs 52/129, P = .002), and lacked EGFR amplification (0/21 vs 26/128, P = .02). The median survival was 19.6 months in H3 K27M-mutant gliomas and 17 months in IDH/H3 wild-type gliomas (P = .3).
In adults, as in children, H3 K27M mutations define a distinct subgroup of IDH wild-type gliomas characterized by a constant midline location, low rate of MGMT promoter methylation, and poor prognosis.
弥漫性 H3 K27M 突变型神经胶质瘤主要发生在儿童中,但也可发生于成年人。本研究旨在描述成人 H3 K27M 突变型神经胶质瘤的特征。
我们分析了 21 例成人 H3 K27M 突变型神经胶质瘤的特征,并与 135 例无组蛋白 H3 且无异柠檬酸脱氢酶(IDH)突变(IDH/H3 野生型)的成人弥漫性神经胶质瘤进行了比较。
H3 K27M 突变型神经胶质瘤的中位诊断年龄为 32 岁(范围:18-82 岁)。所有肿瘤均位于中线部位(脊髓 6 例,丘脑 5 例,脑干 5 例,小脑 3 例,下丘脑 1 例,松果体区 1 例),且 IDH 和 BRAF-V600E 野生型。H3 K27M 突变的鉴定显著影响了 3 例(14%)患者的诊断,这些患者的组织学表现最初提示弥漫性低级别胶质瘤,也影响了 7 例(33%)患者的诊断,这些患者的病理分析在弥漫性神经胶质瘤、神经节胶质瘤或毛细胞星形细胞瘤之间犹豫不决。与 IDH/H3 野生型神经胶质瘤相比,H3 K27M 突变型神经胶质瘤的诊断年龄更早(32 岁 vs 64 岁,P<0.001),均位于中线部位(21/21 例 vs 21/130 例,P<0.001),甲基化 MGMT 启动子频率较低(1/21 例 vs 52/129 例,P=0.002),且缺乏 EGFR 扩增(0/21 例 vs 26/128 例,P=0.02)。H3 K27M 突变型神经胶质瘤的中位生存期为 19.6 个月,IDH/H3 野生型神经胶质瘤为 17 个月(P=0.3)。
在成年人中,与儿童一样,H3 K27M 突变定义了一组独特的 IDH 野生型神经胶质瘤亚组,其特征为恒定的中线位置、MGMT 启动子甲基化率低和预后不良。